Baxter has reported Q2 revenues of $2.96bn, corresponding to a year-over-year (YoY) uplift of 5%, striking an optimistic tone regarding its financial fortunes following a series of setbacks throughout 2025.
The Illinois-based company’s Q2 was driven by sales of $2.1bn in its medical products and therapies segment, indicative of a 7% rise YoY. The company’s healthcare systems and technologies segment meanwhile grew by 4%, generating $801m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Q2 performance prompted Baxter to raise its 2026 outlook, with reported sales growth revised to between 3% and 4% from 1% previously, and earnings projected to land in the $1.95 to $2.15 per diluted share range, up from $1.85 to $2.05 previously.
Baxter released its Q2 results ahead of market open. Shortly after a flat open at $24.40, the company’s shares on the New York Stock Exchange (NYSE) rose by around 17% to $29.07 on 30 July [correct as of 10:00 ET], versus a previous close at $24.77. Baxter has a market cap of $12.79bn.
“Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance,” said Baxter’s president and CEO, Andrew Hider.
“While we’re encouraged by this steady progress and core operating momentum, we remain focused on the work ahead,” Hider continued.
Baxter’s Q2 2025 performance was affected by the long-lasting impact of damage caused to its North Carolina-based facility during Hurricane Helene in September 2024. Baxter produces around 60% of the US supply of IV fluids. By November 2024, around 86% of healthcare providers were reporting shortages.
This issue, along with “softness in demand” for Baxter’s infusion therapies and technologies portfolio, likely exacerbated by a slew of infusion pump recalls throughout recent years, caused its Q2 2025 revenues to come in below analysts’ estimates at $2.81bn.
Baxter launched its growth and performance system (GPS) in October 2025, likely in part to tighten up its internal protocols to address recent issues with products including its Novum infusion pump.
Hider continued: “Guided by the Baxter GPS, we’re focused on further stabilising the business, strengthening the balance sheet and driving a culture of continuous improvement as we build a stronger, more resilient company.”
